Terms: = Breast cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Treatment
28 results:
1. cdk12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract] [Full Text] [Related]
2. treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and clinical landscape of ER + /PR- breast cancer in China.
Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of a novel dual-target inhibitor of cdk12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
[TBL] [Abstract] [Full Text] [Related]
5. PhosphoDisco: A Toolkit for Co-regulated Phosphorylation Module Discovery in Phosphoproteomic Data.
Schraink T; Blumenberg L; Hussey G; George S; Miller B; Mathew N; González-Robles TJ; Sviderskiy V; Papagiannakopoulos T; Possemato R; Fenyö D; Ruggles KV
Mol Cell Proteomics; 2023 Aug; 22(8):100596. PubMed ID: 37394063
[TBL] [Abstract] [Full Text] [Related]
6. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
[TBL] [Abstract] [Full Text] [Related]
7. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract] [Full Text] [Related]
8. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
9. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract] [Full Text] [Related]
10. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
11. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract] [Full Text] [Related]
12. First-in-human HER2-targeted Bispecific Antibody KN026 for the treatment of Patients with HER2-positive Metastatic breast cancer: Results from a Phase I Study.
Zhang J; Ji D; Cai L; Yao H; Yan M; Wang X; Shen W; Du Y; Pang H; Lai X; Zeng H; Huang J; Sun Y; Peng X; Xu J; Yang J; Yang F; Xu T; Hu X
Clin Cancer Res; 2022 Feb; 28(4):618-628. PubMed ID: 34844975
[TBL] [Abstract] [Full Text] [Related]
13. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
[TBL] [Abstract] [Full Text] [Related]
14. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
15. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
[TBL] [Abstract] [Full Text] [Related]
16. cdk12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract] [Full Text] [Related]
17. The promise and current status of cdk12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract] [Full Text] [Related]
18.
Ichimaru Y; Kanaeda N; Tominaga S; Suzui M; Maeda T; Fujii H; Nakao M; Yoshioka H
Nagoya J Med Sci; 2020 Aug; 82(3):509-518. PubMed ID: 33132435
[No Abstract] [Full Text] [Related]
19. cdk12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract] [Full Text] [Related]
20. Th e role of cdk12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract] [Full Text] [Related]
[Next]
